Relationships with debuts
New listing of GENOMTEC S.A. on NewConnect
The company GENOMTEC S.A. was newly listed on NewConnect on 17 March 2021.
GENOMTEC S.A. is the 376th company listed on NewConnect and the sixth new listing on NewConnect in 2021.
Key information
|
name |
GENOMTEC S.A. |
|
seat |
Wrocław |
|
companies listed on NewConnect |
376 |
|
new listings on NewConnect in 2021 |
6 |
|
business sector |
Biotechnology |
|
companies in the sector |
11 |
|
core business |
The core business of Genomtec S.A. is to conduct research and development for applications of isothermal methods in molecular diagnostics |
|
subscription/sale |
Public offering of 730,000 series J shares at an issue price of PLN 11 per share, total value PLN 8,030,000 |
|
reference price* |
PLN 11 |
|
company valuation* |
PLN 89,743,940 |
|
value of introduced instruments* |
PLN 72,802,730 |
|
% free float (under 5% in shares subject to the application) |
44,82 |
|
free float value* (in shares subject to the application) |
PLN 32,630,829 |
|
% free float (under 5% in all shares) |
46.29 |
|
free float value* (in all shares) |
PLN 41,542,039 |
|
Authorised Advisor |
INC S.A. |
|
Market Maker |
Dom Maklerski BOŚ S.A. |
*reference price equal to the issue price of series J shares
History/Core business
The company Genomtec S.A. was established in 2016 by a group of researchers and engineers with experience and competences in molecular biology, microsystems and photonics. The company runs its operations (office and laboratories) from the Łukasiewicz Research Network of the Polish Centre for Technology Development (PORT) in Wrocław at 147, Stabłowicka St.
The core business of Genomtec S.A. is to conduct research and development for applications of isothermal methods in molecular diagnostics. The company’s flagship project Genomtec ID is a diagnostic system which may set a new standard in diagnostics thanks to the mobility, speed and efficiency of the device which detects pathogens such as viruses, bacteria and fungi as well as genetic mutations by analysing biological material (swabs, urine, saliva).
Another business segment of the Company is to develop and commercialise tests used among others in the detection of viral infectious diseases, including the currently urgent medical needs during the COVID-19 pandemic spread by the SARS-CoV-2 virus. The Company has developed the dual-gene test Genomtec® SARS-CoV-2 EvaGreen® RT-LAMP CE-IVD Duo Kit which has been registered and approved for marketing in November 2020 (the test can identify genes by means of a fluorescence signal). The Company had previously registered and marketed a single-gene test in June 2020.
The Company’s share capital according to its entry in the KRS business register is PLN 815,854.00 divided into 8,158,540 series A to J ordinary bearer shares with a nominal value of PLN 0.10 per share.
Public offering of 730,000 series J shares
The subscription opened on 26 October 2020 and closed on 9 November 2020. Series J shares were taken up at an issue price of PLN 11. The shares were allotted to 111 natural persons and 12 legal persons. The offering value was PLN 8,030,000.
Sale of shares by shareholders
According to information published in the information document, there were 44 transactions in 2,204,561 shares of the Company at prices ranging from PLN 0 (donation) to PLN 13 per share from 5 February 2020 to 9 February 2021.
Shareholders
|
Shareholder |
Number of shares |
% of total vote |
% of share capital |
|
Leonarto Funds SCSp |
1,650,620 |
20.23% |
20.23% |
|
Miron Tokarski |
1,456,791 |
17.86% |
17.86% |
|
Małgorzata |
|
|
|
|
Konrad Krajewski |
427,860 |
5.24% |
5.24% |
|
Henryk Roguszczak |
408,360 |
5.01% |
5.01% |
|
Other |
3,776,549 |
46.29% |
46.29% |
|
Total |
8,158,540 |
100% |
100% |
Selected financials of the Issuer (PLN):
|
|
Q1-4 2020 |
31.12.2019 |
31.12.2018 |
|
Equity |
7,393,552.38 |
941,467.46 |
432,372.96 |
|
Liabilities and provisions |
895,735.02 |
1,253,546.53 |
41,093.39 |
|
Total assets |
8,289,287.40 |
2,195,013.99 |
473,466.35 |
|
Core revenue |
20,346.23 |
152,716.28 |
11,437.20 |
|
Net profit |
(1,819,114.28) |
(1,619,237.39) |
(742,712.72) |
|
Total net cash flows* |
5,873,814.62 |
- |
- |
|
Cash flows – closing balance* |
7,301,446.55 |
- |
- |
6,618,430 series A, B, C, D, E, F and J ordinary bearer shares issued by GENOMTEC S.A. have been introduced to trading on NewConnect.